多索茶碱联合布地奈德治疗支气管哮喘急性发作的疗效

Effect of doxofylline combined with budesonide on acute attack of bronchial asthma

目的研究布地奈德联合多索茶碱治疗支气管哮喘急性发作患者的临床疗效。方法选取新疆四七四医院2021年1月-2022年1月收治的100例支气管哮喘急性发作患者,根据治疗方案不同分为对照组(50例)和观察组(50例)。两组均给予常规治疗,对照组采用布地奈德治疗,观察组采用多索茶碱联合布地奈德治疗。比较两组临床疗效、治疗前后肺功能指标、炎性因子水平及不良反应。结果两组治疗后临床疗效比较,观察组96.00%高于对照组的78.00%(P<0.05);治疗后,观察组第1秒最大呼气量(FEV_(1))、呼气流速峰值(PEF)、用力肺活量(FVC)水平均高于对照组(P<0.05);治疗后,观察组痰-嗜酸性粒细胞(痰Eos)、白介素-6(IL-6)、超敏C反应蛋白(hs-CRP)水平均低于对照组(P<0.05);两组不良反应对比,无显著差异(P>0.05)。结论布地奈德联合多索茶碱治疗支气管哮喘急性发作患者的临床疗效确切,可有效减轻机体炎性反应,改善患者肺功能,且安全性良好。

Objective To study the clinical efficacy of budesonide combined with doxofylline in the treatment of patients with acute attack of bronchial asthma.Methods 100 patients with acute attack of bronchial asthma admitted to our hospital from January 2021 to January 2022 were divided into control group(50 cases)and observation group(50 cases)according to different treatment plans.The two groups were given conventional treatment,the control group was treated with budesonide,the observation group was treated with doxofylline combined with budesonide.The clinical efficacy,pulmonary function index,inflammatory factor level and adverse reactions were compared between the two groups.Results The clinical efficacy of observation group was 96.00% higher than control group 78.00%(P<0.05).After treatment,the maximum expiratory volume(FEV_(1)),peak expiratory flow rate(PEF)and forced vital capacity(FVC)levels in the first second of observation group were higher than those in control group(P<0.05).After treatment,the levels of sputum eosinophils(sputum Eos),interleukin-6(IL-6)and hypersensitive C-reactive protein(hs-CRP)in observation group were lower than those in control group(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion Budesonide combined with doxofylline is effective in the treatment of patients with acute attack of bronchial asthma,which can effectively reduce inflammatory response and improve lung function,with good safety.